@article{8b8a3c7d6b554e71832949ff68eb778a,
title = "Three doses of mRNA COVID-19 vaccine protects from SARS-CoV-2 infections in Japan",
keywords = "COVID-19, SARS-CoV-2, vaccine",
author = "Katsuyuki Hotta and Etsuji Suzuki and Eiki Ichihara and Katsuyuki Kiura",
note = "Funding Information: Katsuyuki Hotta received honoraria from Pfizer, AZ, Chugai, Lilly, Takeda, MSD, BMS, Ono, Taiho, and Boehringer‐Ingelheim unrelated to the work, and grants from MSD, AZ, Chugai, Lilly, BMS, and Abbvie unrelated to the work. Etsuji Suzuki has no conflicts of interest. Eiki Ichihara has received honoraria from Eli Lilly Japan, and research funds from MSD, Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Janssen Pharmaceutical K.K. unrelated to the work. Katsuyuki Kiura received consulting fees from Daiichi Sankyo Co., Ltd., honoraria from Eli Lilly Japan K.K., Novartis International AG, Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd., Bristol‐Myers Squibb K.K., MSD K.K., Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., and Daiichi Sankyo Co., Ltd., and grants from Daiichi Sankyo Co., Ltd., TEIJIN Pharma Ltd., Pfizer Japan Inc., SHIONOGI \& Co., Ltd., Boehringer Ingelheim Co., Ltd., Nippon Kayaku Co., Ltd., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd., MSD K.K., Chugai Pharmaceutical Co., Ltd., Bristol‐Myers Squibb K.K., Merck Biopharma Co., Ltd, Novartis International AG, and Takeda Pharmaceutical Co., Ltd., unrelated to the work the work. ",
year = "2022",
month = oct,
doi = "10.1111/joim.13526",
language = "English",
volume = "292",
pages = "687--689",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",
}
SDG 3 すべての人に健康と福祉を